Answers are grounded in this paper and cite their sources.
Background: Chronic liver disease (CLD) is a significant health concern globally, often linked to lifestyle factors such as alcohol consumption and obesity. Early identification and intervention are crucial for preventing disease progression. Liver stiffness measurement (LSM) using transient elastography (FibroScan) is a non-invasive method for assessing liver fibrosis, but factors influencing its accuracy need further exploration. This study aims to investigate predictors of liver stiffness and fibrosis in patients with CLD. Methods: A retrospective cross-sectional study was conducted at the Kurdistan Center for Gastroenterology and Hepatology (KCGH) in Iraq from June to December 2019. Medical records of 609 CLD patients who underwent LSM by FibroScan were analyzed. Sociodemographic data, liver function tests, liver size, and fibrosis stage were collected. Multivariate linear regression analysis was performed to identify predictors of LSM. Results: Hepatitis B (47.3%) and non-alcoholic fatty liver disease (NAFLD) (17.9%) were prevalent diagnoses. Liver stiffness ranged from 2.7 to 71.6 kPa, with a mean of 8.8 kPa. Fibrosis staging revealed 38.3% at F0, 23.5% at F1, and 9.2% at F4. Significant associations were found between liver enzyme abnormality, liver size, controlled attenuation parameter (CAP), and fibrosis. Multivariate regression identified fibrosis grade (OR: 4.431), liver disease type (OR: 0.338), and liver size (OR: 3.025) as predictive of FibroScan liver stiffness values (p<0.001). Advanced fibrosis (F4) correlated with elevated alanine aminotransferase (ALT) levels and hepatomegaly. Conclusion: Liver stiffness, fibrosis stage, liver enzyme abnormalities, and liver size are important predictors of fibrosis in patients with CLD. Early detection and intervention are crucial in managing CLD patients, especially those with hepatitis B and NAFLD. Further research is needed to explore additional predictors and refine diagnostic algorithms for better risk stratification and treatment guidance in CLD.
No takes yet. Share an insight, caveat, or question.
A 2024 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: